News

This project will test a new strategy for selectively killing tumor cells in triple-negative breast cancer (TNBC), an aggressive breast cancer subtype with particularly poor prognosis for which no targeted therapies are currently available. This strategy leverages clinically approved therapeutics to exploit a molecular vulnerability that we recently discovered in tumors with uncontrolled activation of the master metabolic regulator mTOR complex 1. We hypothesize that this strategy could be effective in killing TNBC cells in which mTORC1 is activated by specific genetic mutations which are common in breast cancer. The use of clinically approved therapeutics means that efficacy in these studies could lead to their rapid repurposing for breast cancer patients.

This project will test a new strategy for selectively killing a molecular subtype of T-cell acute lymphoblastic leukemia (T-ALL) using drugs that are already being used in humans as safe and well-tolerated immunosuppressants. This strategy exploits a molecular vulnerability that we recently discovered in tumors with abnormal activation of mTOR complex 1 (mTORC1), which is activated to promote cell growth and proliferation in the majority of human cancers. We discovered that tumor cells with active mTORC1 could be selectively killed, without affecting normal cells, in pre-clinical models of a genetic tumor syndrome called Tuberous Sclerosis Complex (TSC), in which tumor growth is driven by high mTORC1 activity. Due to key molecular similarities between cells in TSC tumors and T-ALL, we hypothesize that the same strategy could be effective in killing T-ALL cells in which mTORC1 is activated by specific genetic mutations which are common in leukemia and lymphoma. The use of clinically approved therapeutics means that efficacy in these studies could lead to rapid repurposing of these drugs for leukemia patients.